Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA01IB
|
|||
| Drug Name |
MTL-CEPBA
|
|||
| Drug Type |
Small activating RNA
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1/2 | [1] | |
| Company |
MiNA Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CEBPA messenger RNA (CEBPA mRNA) | Target Info | Activator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of MiNA Therapeutics. | |||
| REF 2 | MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.